Abstract
Heterogeneous in size (0.1-1 µm), microparticles are small membrane vesicles released from activated and/or apoptotic cells. Although described since 1967 by Wolf [1], it is only since the 1990’s that microparticles have been considered as biomarkers as well as potential mediators of biological messages between cells [2] by acting as paracrine and endocrine vectors. Detection of microparticles has been performed in biological fluids (blood, synovial fluid, saliva for instance) and some solid tissues but also from the culture medium [3]. Levels of circulating microparticles are enhanced in a large number of pathological states including cardiovascular and metabolic disorders associated with insulin resistance and this has been linked to deleterious effects on cells from the vascular wall, mainly, endothelial cells. This review highlights the increasing impact of microparticles in major cardiovascular pathological situations associated with metabolic derangements.
Keywords: Diabetes, endothelium, extracellular vesicles, hypertension, obesity.
Current Vascular Pharmacology
Title:Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components
Volume: 12 Issue: 3
Author(s): Abdelali Agouni, Ramaroson Andriantsitohaina and Maria C. Martinez
Affiliation:
Keywords: Diabetes, endothelium, extracellular vesicles, hypertension, obesity.
Abstract: Heterogeneous in size (0.1-1 µm), microparticles are small membrane vesicles released from activated and/or apoptotic cells. Although described since 1967 by Wolf [1], it is only since the 1990’s that microparticles have been considered as biomarkers as well as potential mediators of biological messages between cells [2] by acting as paracrine and endocrine vectors. Detection of microparticles has been performed in biological fluids (blood, synovial fluid, saliva for instance) and some solid tissues but also from the culture medium [3]. Levels of circulating microparticles are enhanced in a large number of pathological states including cardiovascular and metabolic disorders associated with insulin resistance and this has been linked to deleterious effects on cells from the vascular wall, mainly, endothelial cells. This review highlights the increasing impact of microparticles in major cardiovascular pathological situations associated with metabolic derangements.
Export Options
About this article
Cite this article as:
Agouni Abdelali, Andriantsitohaina Ramaroson and Martinez C. Maria, Microparticles as Biomarkers of Vascular Dysfunction in Metabolic Syndrome and its Individual Components, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/1570161112666140423223148
DOI https://dx.doi.org/10.2174/1570161112666140423223148 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Altered Calmodulin Degradation and Signaling in Non-Neuronal Cells from Alzheimer’s Disease Patients
Current Alzheimer Research Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle
Current Pharmaceutical Design Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Effects of a Long-Term Treatment with an Antioxidant Pyridoindole on Vascular Responsiveness in Diabetes-Induced Aging Rats
Current Aging Science Fabry Disease and Cardiovascular Involvement
Current Pharmaceutical Design Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Decoding the Transcriptional Response to Ischemic Stroke in Obese and Non-obese Mice Brain
Current Neurovascular Research Clinical Impacts in Cardiovascular Molecular Imaging: the Example of Cardiac Sympathetic Imaging in Heart Failure
Current Medical Imaging Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews